- QMRO Home
- Barts Cancer Institute
- Centre for Experimental Cancer Medicine
- Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer
Browse
Administrators only